Compare DexCom, Inc. (DXCM) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? DexCom, Inc. trades at $84.01 (market cap $31.86B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.45 (market cap $962.24M). The key difference: DexCom, Inc. is far larger — about 33.1× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 56 Days on average.
| DXCM | QDTE | |
|---|---|---|
Market Cap | $31.86B | $962.24M |
Volume | 3,607,070 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $92.34 | $36.60 |
52-Week Low | $54.84 | $26.85 |
Typical Hold Time | 62 Days | 56 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
QDTE trades at $29.89, down 0.3% with a bullish technical signal despite overbought RSI readings. The ETF generates weekly income through covered call strategies but faces concerns about NAV erosion and return of capital. Recent distributions have declined from $0.28 to $0.11, reflecting shrinking yields as volatility decreases. The fund's 0.97% expense ratio consumes significant portions of payouts, creating structural challenges for long-term value preservation.
The outlook remains cautious as high distribution yields mask underlying NAV deterioration. While weekly income appeals to retail investors, the strategy underperforms in bull markets and faces sustainability questions. Key risks include volatility dependency, return of capital concerns, and competitive pressure from alternative income ETFs. Analyst sentiment is mixed with recent downgrades highlighting structural weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
